BDTX Q3 2022 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

BDTXBlack Diamond Therapeutics, Inc.

$125M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$22M

EPS (Diluted)

$-0.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$180M

Total Liabilities

$47M

Stockholders' Equity

$133M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$35M	+37.4%
Net Income	-$22M	-$35M	+38.3%